Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anetumab Ravtansine + Atezolizumab in NSCLC
NCT03455556Phase 1Terminated
- Sponsor
- Mayo Clinic
- Start
- Aug 2018
- Primary completion
- Sep 2019
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anetumab ravtansine in non-small cell lung cancer (NSCLC), sponsored by Mayo Clinic. Primary endpoints: Maximum Tolerated Dose up to 21 days and Confirmed Response Rate at 6 months. Started Aug 2018; status: terminated.
02
Drugs
anetumab ravtansine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03455556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03455556.